Gremillet Marion, Talon Laurie, Lebreton Aurélien, Sinegre Thomas
CHU Clermont-Ferrand, Service d'hématologie Biologique, 1 Place Lucie Et Raymond Aubrac, 63003, Clermont-Ferrand, France.
Université Clermont Auvergne, Unité de Nutrition Humaine, UMR INRAE/UCA 1019, Clermont-Ferrand, France.
Thromb J. 2023 Feb 20;21(1):21. doi: 10.1186/s12959-023-00465-8.
Anti-factor Xa assays and activated partial thromboplastin time (aPTT) are mainly employed to monitor patients treated with heparins. According to the Clinical and Laboratory Standards Institute and the French Working Group on Haemostasis and Thrombosis, anti-factor Xa activity and aPTT should be tested within 2 h of blood sampling for unfractionated heparin (UFH) monitoring. However, discrepancies exist depending on the used reagents and collecting tubes. The study aim was to determine the stability of aPTT and anti-factor Xa measurements using blood samples collected in citrate-containing or citrate-theophylline-adenosine-dipyridamole (CTAD) tubes and stored for up to 6 h.
Patients receiving UFH or low molecular weight heparin (LMWH) were enrolled; aPTT and anti-factor Xa activity were tested using two different analyser/reagent pairs (Stago and reagent without dextran sulfate; Siemens and reagent with dextran sulfate) after 1, 4 and 6 h of sample storage as whole blood or as plasma.
For UFH monitoring, comparable anti-factor Xa activity and aPTT results were obtained with both analyser/reagent pairs when samples were stored as whole blood before plasma isolation. With samples stored as plasma, anti-factor Xa activity and aPTT were not affected up to 6 h after sampling when using the Stago/no-dextran sulfate reagent pair. With the Siemens/dextran sulfate-containing reagent, aPTT was significantly altered after 4 h of storage. For LMWH monitoring, anti-factor Xa activity remained stable (whole blood and plasma) for at least 6 h. Results were comparable with citrate-containing and CTAD tubes.
Anti-factor Xa activity in samples stored as whole blood or plasma was stable for up to 6 h, regardless of the reagent (with/without dextran sulfate)/collection tube. Conversely, aPTT was more variable because other plasma parameters can influence its measure and complicate the interpretation of its variations after 4 h.
抗Xa因子检测和活化部分凝血活酶时间(aPTT)主要用于监测接受肝素治疗的患者。根据临床和实验室标准协会以及法国止血与血栓形成工作组的建议,在监测普通肝素(UFH)时,抗Xa因子活性和aPTT应在采血后2小时内进行检测。然而,根据所使用的试剂和采血管不同,检测结果存在差异。本研究的目的是确定使用枸橼酸盐管或枸橼酸盐-茶碱-腺苷-双嘧达莫(CTAD)管采集并储存长达6小时的血样中aPTT和抗Xa因子检测结果的稳定性。
纳入接受UFH或低分子量肝素(LMWH)治疗的患者;将血样作为全血或血浆储存1、4和6小时后,使用两种不同的分析仪/试剂组合(思塔高公司和不含硫酸葡聚糖的试剂;西门子公司和含硫酸葡聚糖的试剂)检测aPTT和抗Xa因子活性。
对于UFH监测,当血样在分离血浆前作为全血储存时,两种分析仪/试剂组合获得的抗Xa因子活性和aPTT结果具有可比性。当血样作为血浆储存时,使用思塔高公司/不含硫酸葡聚糖的试剂组合,采血后6小时内抗Xa因子活性和aPTT不受影响。使用西门子公司/含硫酸葡聚糖的试剂时,储存4小时后aPTT显著改变。对于LMWH监测,抗Xa因子活性(全血和血浆)至少6小时保持稳定。使用枸橼酸盐管和CTAD管的结果具有可比性。
无论试剂(含/不含硫酸葡聚糖)/采血管如何,作为全血或血浆储存的样本中的抗Xa因子活性在长达6小时内保持稳定。相反,aPTT变化更大,因为其他血浆参数会影响其测量结果,并使4小时后其变化的解读变得复杂。